Abstract
Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disease. Nusinersen is the first pharmacologic therapy approved for treatment of SMA. More research is needed to understand the real-world economic benefits of nusinersen treatment. Healthcare utilization and costs of patients treated with nusinersen were investigated using US hospital-based administrative data.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
